Market Overview

UPDATE: ISI Group Cuts PT to $39 on Charles River Laboratories Following Negative Guidance

Related CRL
Top 4 NYSE Stocks In The Medical Laboratories & Research Industry With The Highest ROE
Charles River Beats on Q2 Earnings & Revenues, Outlook Upped

ISI Group reiterated its Underweight rating on Charles River Laboratories (NYSE: CRL) and lowered its price target from $40.50 to $39.

ISI Group commented, "As a result of today's 2013 guidance announcement, we are lowering CRL's FY13 EPS from $3.10 to $3.00 and FY14 EPS from $3.45 to $3.25. These EPS changes stem from lower operating margin expectations due to the aforementioned investment headwinds. Despite the improved revenue outlook, limited visibility across the business (ex strategic deals) and a challenged OM outlook will limit P/E expansion, and in turn, cap shares in the upper $30s."

Charles River Laboratories closed at $36.55 on Tuesday.

Latest Ratings for CRL

DateFirmActionFromTo
Nov 2014Credit SuisseMaintainsNeutral
Nov 2014CitigroupMaintainsNeutral
Oct 2014Deutsche BankMaintainsHold

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

Posted-In: ISI GroupAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (CRL)

Around the Web, We're Loving...

Get Benzinga's Newsletters